SGLT2 Inhibition in Hemodialysis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT05179668

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05179668
  • EudraCT 2021-000733-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05179668. Randomized; triple masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2025-07-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibition in Hemodialysis
Acronym
DAPA-HD
Condition
Kidney Failure
Condition
Hemodialysis
Condition
Diabetes Mellitus, Type 2
Condition
Left Ventricular Hypertrophy
Intervention (Drug)
Dapagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
Medical University of Vienna (class: other)

Record details

Record id
cardio:ct-nct05179668
Content hash
c9e94ba0a4c75cd437056707d37a00e45fac30f450f2ad60378f222acb1aff86